Shape Biopharmaceuticals gets the CHF 150,000 Kick to challenge conventional immunotherapy methods
14.11.2024
Drawing up a new class of structurally defined, 3D-optimized, engineered nanomedicines that leverage the immune system for chronic diseases, biotech startup Shape Biopharmaceuticals has received the final CHF 150,000 from Venture Kick to generate personalized therapeutic antibodies directly in patients.
 CSO Armando Zuniga and CEO Arin Ghasparian
|
 |
The increasing pressure on healthcare systems, driven by rising demand for services and resource constraints, highlights the urgent need for innovative strategies in disease prevention and treatment. Traditional approaches often encounter challenges such as lengthy development timelines, high costs, and limited accessibility, preventing the effective delivery of immunotherapies to millions of patients worldwide.
Shape Biopharmaceuticals is addressing this challenge with its proprietary SHAPEnano particles, a technology that enables patients' immune systems to produce therapeutic antibodies internally. This approach improves the accessibility and affordability of immunotherapies, allowing patients to benefit from just two to three doses per year compared to the considerably higher amounts typically required. Additionally, it reduces the risk of anti-drug antibodies and delivers substantial cost savings, distinguishing Shape in the market and expanding treatment options for many.
Chronic diseases are on the rise globally, with projected costs exceeding CHF 40 trillion by 2030. The immunotherapy market is also primed for significant growth, estimated to reach CHF 173 billion by 2030, growing at an annual rate of 12%. Despite this, many conditions remain undertreated. Shape Biopharmaceuticals is well-positioned to bridge these gaps by delivering affordable, innovative solutions that enhance access and improve outcomes for a broad range of patients.
Shape Biopharmaceuticals will leverage the CHF 150,000 from Venture Kick to accelerate business and product development, progressing strategic initiatives aimed at delivering innovative treatments.
The company was founded by repeat biotech entrepreneurs CEO Arin Ghasparian and CSO Armando Zuniga, who both have a longstanding track record of successfully developing novel vaccine and drug delivery technologies from scratch to clinic.
"Venture Kick has been a key support in our journey, providing essential early-stage funding and constructive feedback to develop our company. Its backing has strengthened Shape’s foundation, accelerating our progress toward bringing advanced immunotherapy solutions to market," stated Arin Ghasparian.
CSO Armando Zuniga and CEO Arin Ghasparian
Shape Biopharmaceuticals is addressing this challenge with its proprietary SHAPEnano particles, a technology that enables patients' immune systems to produce therapeutic antibodies internally. This approach improves the accessibility and affordability of immunotherapies, allowing patients to benefit from just two to three doses per year compared to the considerably higher amounts typically required. Additionally, it reduces the risk of anti-drug antibodies and delivers substantial cost savings, distinguishing Shape in the market and expanding treatment options for many.
Chronic diseases are on the rise globally, with projected costs exceeding CHF 40 trillion by 2030. The immunotherapy market is also primed for significant growth, estimated to reach CHF 173 billion by 2030, growing at an annual rate of 12%. Despite this, many conditions remain undertreated. Shape Biopharmaceuticals is well-positioned to bridge these gaps by delivering affordable, innovative solutions that enhance access and improve outcomes for a broad range of patients.
Shape Biopharmaceuticals will leverage the CHF 150,000 from Venture Kick to accelerate business and product development, progressing strategic initiatives aimed at delivering innovative treatments.
The company was founded by repeat biotech entrepreneurs CEO Arin Ghasparian and CSO Armando Zuniga, who both have a longstanding track record of successfully developing novel vaccine and drug delivery technologies from scratch to clinic.
"Venture Kick has been a key support in our journey, providing essential early-stage funding and constructive feedback to develop our company. Its backing has strengthened Shape’s foundation, accelerating our progress toward bringing advanced immunotherapy solutions to market," stated Arin Ghasparian.
CSO Armando Zuniga and CEO Arin Ghasparian